WEDNESDAY, Aug. 20, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk’s popular weight-loss drug Wegovy to treat a serious form of fatty liver disease. The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderateContinue Reading